Skip to content
Glostarep
Menu
Startups
AI Core
More
Glostarep Voices
Venture Capital
The Startup’s Table
Interviews
Subscribe
Startups
AI Core
More
Glostarep Voices
Venture Capital
The Startup’s Table
Interviews
Subscribe
Subscribe
Startups
AI Core
More
Glostarep Voices
Venture Capital
The Startup’s Table
Interviews
Venture Capital
Ollin Biosciences Bags $330M to Take Eye Drug Into Phase 3
Glostarep
/
June 24, 2026
